CoChat

Amyloid precursor protein and endosomal-lysosomal dysfunction in Alzheimer's disease: inseparable partners in a multifactorial disease

Open access
Nixon, Ralph A. · 2017 · The FASEB Journal

The DOI matches its Crossref record; 216 of the 218 references it cites were found in a registry or an index.

Abstract

Abnormalities of the endosomal–lysosomal network (ELN) are a signature feature of Alzheimer's disease (AD). These include the earliest known cytopathology that is specific to AD and that affects endosomes and induces the progressive failure of lysosomes, each of which are directly linked by distinct mechanisms to neurodegeneration. The origins of ELN dysfunction and β‐amyloidogenesis closely overlap, which reflects their common genetic basis, the established early involvement of endosomes and lysosomes in amyloid precursor protein (APP) processing and clearance, and the pathologic effect of certain APP metabolites on ELN functions. Genes that promote β‐amyloidogenesis in AD (APP, PSEN1/2, and APOE4) have primary effects on ELN function. The importance of primary ELN dysfunction to pathogenesis is underscored by the mutations in more than 35 ELN‐related genes that, thus far, are known to cause familial neurodegenerative diseases even though different pathogenic proteins may be involved. In this article, I discuss growing evidence that implicates AD gene–driven ELN disruptions as not only the antecedent pathobiology that underlies β‐amyloidogenesis but also as the essential partner with APP and its metabolites that drive the development of AD, including tauopathy, synaptic dysfunction, and neurodegeneration. The striking amelioration of diverse deficits in animal AD models by remediating ELN dysfunction further supports a need to integrate APP and ELN relationships, including the role of amyloid‐β, into a broader conceptual framework of how AD arises, progresses, and may be effectively therapeutically targeted.—Nixon, R. A. Amyloid precursor protein and endosomal–lysosomal dysfunction in Alzheimer's disease: inseparable partners in a multifactorial disease. FASEB J. 31, 2729–2743 (2017). www.fasebj.org

Overview

Integrity signals

Registry

Crossref · 10.1096/fj.201700359

Cites

216 of 216 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

19 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

2 retracted

Items 201–216 of 216

Research works printed but not linked: 1

  1. 10.1111/j.1365-2990.2010.01062.x · doi:10.1111/j.1365-2990.2010.01062.x · Paper page

Cited by

See all 407

Metadata

Authors
Nixon, R. A.
Affiliations
Nathan Kline Institute for Psychiatric Research (US)
Corresponding author
Nixon, Ralph A.
Venue
The FASEB Journal
Publisher
Wiley
Published
2017-06-14
Volume
31
Issue
7
Pages
2729-2743
ISSN
  • 0892-6638 (ISSN-L)
  • 1530-6860
OpenAlex
W2728546490
Cited by
400
References
218
Citations by year
2026: 39 · 2025: 55 · 2024: 44 · 2023: 36 · 2022: 50 · 2021: 55 · 2020: 55 · 2019: 34 · 2018: 25 · 2017: 7
FWCI
4.06
Type
journal article
Language
en
Open access
Locations
  • The FASEB Journal (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
Funders
  • National Institutes of Health
  • National Institute on Aging
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
Keywords
Alzheimer's disease, amyloid precursor protein, lysosomal dysfunction, endosomes, APP processing, presenilin 1, presenilin 2, APOE ε4, tauopathy, synaptic dysfunction, neurodegeneration, familial neurodegenerative disease, animal models of Alzheimer's disease, therapeutic target
MeSH terms
Alzheimer Disease, Gene Expression Regulation, Humans, Lysosomes, Endosomes, Amyloid beta-Protein Precursor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.